PAK1 mediates resistance to PI3K inhibition in lymphomas. - Wikidata - wikimedia - TriplyDB

PAK1 mediates resistance to PI3K inhibition in lymphomas.

PAK1 mediates resistance to PI3K inhibition in lymphomas.

http://www.wikidata.org/entity/Q34539577

about

PI3K and AKT: Unfaithful Partners in Cancer What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Group I PAK inhibitor IPA-3 induces cell death and affects cell adhesivity to fibronectin in human hematopoietic cells Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma.miR-155 Controls Lymphoproliferation in LAT Mutant Mice by Restraining T-Cell Apoptosis via SHIP-1/mTOR and PAK1/FOXO3/BIM Pathways PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness.Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies.Bioassay-Guided Isolation and Evaluation of Antiproliferative Effects of (Z)-Ethylidene-4, 6-Dimethoxycoumaran-3-One from Pogostemon Quadrifolius (Benth.)Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.The Genetic Basis of Hepatosplenic T-cell Lymphoma.Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly

P2860

Q26781367-176A9C0E-C70A-4814-AED9-CEFFB839DC22 Q26825780-6FE87226-13E3-4340-86E6-3F49856BF10D Q27026544-F4C47C77-A11B-48F7-9BD2-C6049C629B4F Q27304386-127DCEEE-FAFC-4A0F-80DA-C3F7494B028A Q28541395-542955A5-044B-48BA-A955-E827AF4EA6BA Q30841629-71D83936-DFEE-45E4-832B-6D8D269A1114 Q33706877-F86F58EC-38DA-4991-86E7-51978ACD77D6 Q35167200-E9C2B3FB-15A5-46E8-B371-3040DDB88F9D Q35676981-3D8518A7-9ED3-4FA3-BCBA-1A4ADBD1E75E Q37319857-0660C932-782D-4556-BFCD-5B44467D0574 Q38110087-314AA42D-BCB8-41BC-BE02-16E273499CC2 Q38161760-58DC095A-80D7-495D-9BCD-F2E2FAEA1801 Q38237619-47342F41-2F4D-4766-8896-FB3A38E3B0E5 Q38238607-FFD8173E-874D-459A-B2A6-EA6AC5194B2F Q38651123-E520D03D-47B8-4471-A8FE-0B4686612FB9 Q39145770-B4E5613C-BA7C-40AB-BFE5-BE1FC7D8C503 Q42924738-6D566255-F74F-493E-B279-EAF92C237D36 Q46356479-F297654C-4378-4CE6-96C6-AE37914FD0C0 Q54316519-97797450-94C6-4124-8FBE-0915A1327B47

P2860

PAK1 mediates resistance to PI3K inhibition in lymphomas.

http://www.wikidata.org/entity/Q34539577

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

PAK1 mediates resistance to PI3K inhibition in lymphomas.

@ast

PAK1 mediates resistance to PI3K inhibition in lymphomas.

@en

PAK1 mediates resistance to PI3K inhibition in lymphomas.

@nl

type

label

PAK1 mediates resistance to PI3K inhibition in lymphomas.

@ast

PAK1 mediates resistance to PI3K inhibition in lymphomas.

@en

PAK1 mediates resistance to PI3K inhibition in lymphomas.

@nl

prefLabel

PAK1 mediates resistance to PI3K inhibition in lymphomas.

@ast

PAK1 mediates resistance to PI3K inhibition in lymphomas.

@en

PAK1 mediates resistance to PI3K inhibition in lymphomas.

@nl

P1433

Q34539577-377F67E6-BF20-4CD1-8A65-6F4877DACEDD

P1476

Q34539577-5F815F3D-25F6-4117-AB9C-55DEDAF78B5B

P2093

Q34539577-087534F2-5643-4775-B603-FE324934B93C

Q34539577-2B0AF01D-5441-474E-A8F9-6E758FD9F0C6

Q34539577-575DFF34-6D8B-4651-9F73-379A6EA3EE53

Q34539577-6C885B65-FADC-4CA3-8E91-EB76D87066B9

Q34539577-6E82B70D-26F5-4B85-84F0-169FB969FA46

Q34539577-9BB5A48F-A5D9-43D6-B167-2CFD19D4B68E

Q34539577-A38E908C-2DC1-4EA7-ACFF-EF177EB8E1B0

Q34539577-A3F8D846-8951-4477-BFEB-25ABCC077BFC

Q34539577-F050B521-5509-428E-BC1B-E0C384CC3CA6

P2860

Q34539577-00A3805C-CB0F-421C-AD21-D79693A403F9

Q34539577-086E5B51-A997-4372-B4FB-501BA5F34C04

Q34539577-0E826305-F3FE-466B-8F18-FB24C1989B60

Q34539577-0EF981E0-811E-4910-B680-6879325D82B4

Q34539577-13A80484-8938-42DA-AB79-18C38307F697

Q34539577-1BBDD851-99FB-41FB-8CC0-C347CD660AEC

Q34539577-2045FACF-0736-4ACE-A9D4-798FF0D0C80D

Q34539577-24548149-78CC-48EA-BD6C-79297EDBD195

Q34539577-289F983A-12A2-49F2-B066-0E073A3367ED

Q34539577-2D604BBB-9652-41D7-936B-315E05890208

P304

Q34539577-FE1CA147-EFB0-4B56-9D11-63CA11722997

P31

Q34539577-ECC382A7-6C6E-494F-B93D-0931EC429357

P356

Q34539577-8C19374E-566D-44D1-9EF2-4321E309F794

P407

Q34539577-16717EC0-1CC1-49FE-A950-4E93D235931D

P433

Q34539577-70EA59FA-777F-4038-880D-04E2639F924D

P478

Q34539577-596EB571-DF65-4D62-A568-BF8567177C57

P50

Q34539577-EF491EED-746A-4995-BD1F-DDA22B87F2E1

P577

Q34539577-D2C79EB4-8584-45C6-B488-E26B0FBF4C31

P698

Q34539577-AF7ED1CC-1DD5-43A8-92E8-AC7B08864F54

P921

Q34539577-31B2BD82-8A3B-4A26-9145-523D2977A293

Q34539577-44013DA2-24A9-4B0C-AC69-6F0717B9E066

Q34539577-D218FB50-58EC-4F45-8F2F-139D30E4CE60

P932

Q34539577-C5DACD13-EF39-4070-8706-85D46823F1F3

P356

1078-0432.CCR-12-1060

P1433

Clinical Cancer Research

P1476

PAK1 mediates resistance to PI3K inhibition in lymphomas

@en

P2093

Alice Fan

http://www.w3.org/2001/XMLSchema#string

Amee Patel

http://www.w3.org/2001/XMLSchema#string

Anne Beaven

http://www.w3.org/2001/XMLSchema#string

Cassandra Love

http://www.w3.org/2001/XMLSchema#string

Jason Smith

http://www.w3.org/2001/XMLSchema#string

Katherine Walsh

http://www.w3.org/2001/XMLSchema#string

Matthew S McKinney

http://www.w3.org/2001/XMLSchema#string

Qingquan Liu

http://www.w3.org/2001/XMLSchema#string

Sandeep S Dave

http://www.w3.org/2001/XMLSchema#string

P2860

Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs

The PI3K pathway as drug target in human cancer

Cluster analysis and display of genome-wide expression patterns

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase

Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase

P304

1106-1115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-1060

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23300274

http://www.w3.org/2001/XMLSchema#string

P921

BGT-226 maleate

P932

3594365

http://www.w3.org/2001/XMLSchema#string